BACKGROUND: It is unclear whether it is appropriate to transfer the follow-up care of breast cancer (BrCa) survivors from cancer specialists to primary care physicians (PCPs). This contemporary study compared physician specialty and documented the long-term surveillance of survivors who underwent surgery at an American academic center. METHODS: Women in this institutional review board-approved study underwent breast surgery between 1996 and 2006. Data were collected for 270 patients with stage I to III BrCa (mean follow-up, 6 years). Charts were reviewed based on American Society of Clinical Oncology (ASCO) guidelines for recommended surveillance frequency and care. RESULTS: The majority of patients (90%; n = 242) were followed by specialists with 10% (n = 28) followed by PCPs. Patients with advanced disease and a greater risk of disease recurrence more often received specialist care. Patients followed by specialists were more often seen at ASCO-recommended intervals (eg, 89% vs 69% of patients followed by a PCP at follow-up Year 6; P < .01); however, many patients were followed inconsistently. Breast disease was often not the focus of PCP visits or mentioned in clinic notes (18% patients). Women seen by specialists were more likely to have documented clinical examinations of the breast (93% vs 44% at Year 6), axilla (94% vs 52%), or annual mammograms (74% vs 48%; P = .001-.02). CONCLUSIONS: Consistent compliance with surveillance guidelines and chart documentation needs improvement among all providers; however, specialists more consistently met ASCO guidelines. If transfer of care to a PCP occurs, it should be formalized and include follow-up recommendations and defined physician responsibilities. Providers and patients should be educated regarding surveillance care and current guidelines incorporated into standard clinical practice. (c) 2010 American Cancer Society.
BACKGROUND: It is unclear whether it is appropriate to transfer the follow-up care of breast cancer (BrCa) survivors from cancer specialists to primary care physicians (PCPs). This contemporary study compared physician specialty and documented the long-term surveillance of survivors who underwent surgery at an American academic center. METHODS:Women in this institutional review board-approved study underwent breast surgery between 1996 and 2006. Data were collected for 270 patients with stage I to III BrCa (mean follow-up, 6 years). Charts were reviewed based on American Society of Clinical Oncology (ASCO) guidelines for recommended surveillance frequency and care. RESULTS: The majority of patients (90%; n = 242) were followed by specialists with 10% (n = 28) followed by PCPs. Patients with advanced disease and a greater risk of disease recurrence more often received specialist care. Patients followed by specialists were more often seen at ASCO-recommended intervals (eg, 89% vs 69% of patients followed by a PCP at follow-up Year 6; P < .01); however, many patients were followed inconsistently. Breast disease was often not the focus of PCP visits or mentioned in clinic notes (18% patients). Women seen by specialists were more likely to have documented clinical examinations of the breast (93% vs 44% at Year 6), axilla (94% vs 52%), or annual mammograms (74% vs 48%; P = .001-.02). CONCLUSIONS: Consistent compliance with surveillance guidelines and chart documentation needs improvement among all providers; however, specialists more consistently met ASCO guidelines. If transfer of care to a PCP occurs, it should be formalized and include follow-up recommendations and defined physician responsibilities. Providers and patients should be educated regarding surveillance care and current guidelines incorporated into standard clinical practice. (c) 2010 American Cancer Society.
Authors: Jasmin A Tiro; Joanne M Sanders; L Aubree Shay; Caitlin C Murphy; Heidi A Hamann; L Kay Bartholomew; Lara S Savas; Sally W Vernon Journal: Breast Cancer Res Treat Date: 2015-04-29 Impact factor: 4.872
Authors: Betsy C Risendal; Rebecca L Sedjo; Anna R Giuliano; Susan Vadaparampil; Paul B Jacobsen; Kristin Kilbourn; Anna Barón; Tim Byers Journal: J Cancer Surviv Date: 2015-06-13 Impact factor: 4.442
Authors: Richard G Roetzheim; Jeanne M Ferrante; Ji-Hyun Lee; Ren Chen; Kymia M Love-Jackson; Eduardo C Gonzalez; Kate J Fisher; Ellen P McCarthy Journal: Ann Fam Med Date: 2012 Sep-Oct Impact factor: 5.166
Authors: Mónica E López; Celia P Kaplan; Anna M Nápoles; Jennifer C Livaudais; E Shelley Hwang; Susan L Stewart; Joan Bloom; Leah Karliner Journal: J Cancer Surviv Date: 2013-02-14 Impact factor: 4.442
Authors: Lindsey Enewold; Katherine A McGlynn; Shelia H Zahm; Ismail Jatoi; William F Anderson; Abegail A Gill; Craig D Shriver; Kangmin Zhu Journal: Cancer Date: 2013-08-01 Impact factor: 6.860
Authors: Kathryn E Weaver; Noreen M Aziz; Neeraj K Arora; Laura P Forsythe; Ann S Hamilton; Ingrid Oakley-Girvan; Gretchen Keel; Keith M Bellizzi; Julia H Rowland Journal: J Oncol Pract Date: 2014-04-01 Impact factor: 3.840
Authors: Andrew Ernst; Kathryn E Flynn; Elizabeth M Weil; Bradley H Crotty; Sailaja Kamaraju; Nicole Fergestrom; Joan Neuner Journal: Clin Breast Cancer Date: 2020-07-22 Impact factor: 3.225